Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Early Stage

May 7, 2024

Adjuvant Alectinib for ALK+ NSCLC: An Interview with Dr. Benjamin Solomon

By

Narjust Florez, MD

Early Stage

Speaking with Dr. Narjust Florez, Prof. Solomon discusses the design and results of the ALINA trial.
January 29, 2021

ADAURA: Data is Only Part of the Story

By

Early Stage

Patient Research Advocate (PRA) and 12-year survivor, Jill Feldman, discusses scientific and humanistic concerns regarding the ADAURA trials current data on disease-free progression in NSCLC. As a patient, osimertinib has […]

January 27, 2021

Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC

By

Early Stage, WCLC 2020 Archive

The randomized phase III ADAURA trial stirred up considerable excitement last year when results from an unplanned interim analysis revealed an 80% reduction in the risk of disease recurrence or […]
January 26, 2021

Redefining Good Quality Resections in NSCLC

By

Early Stage, WCLC 2020 Archive

Curative-intent resections for NSCLC often fail. Approximately 20% to 40% of patients with lung cancer who undergo curative-intent resection, experience a relapse, and die within 4 years. One key factor […]